EIA, ELISA(Det), WB We recommend the following for sandwich ELISA (Capture - Detection): DCAB-TJ049 - DCAB-TJ050
General Notes
This antibody was raised against Influenza A haemagglutinin H1 and can be used for the development of an analytical method. We recommend the following as antibody pair (Capture - Detection): DCAB-TJ049 - DCAB-TJ050 Influenza A haemagglutinin H1 (HA H1) is a surface glycoprotein that plays a crucial role in the virus's ability to enter host cells. The H1 subtype is found in seasonal strains of Influenza A, and antibodies targeting HA H1 are commonly used in diagnostic assays to identify and differentiate Influenza A infections.
Target
Alternative Names
Influenza A H1; Influenza Virus Type A Hemagglutinin H1; IAV H1
Citations
Publication ()
Have you cited DCAB-TJ050 in a publication? Let us know and earn a reward for your research.
Development of rapid diagnostic tests for multiplexed detection of COVID-19 and Influenza diseases
Turkish Journal of Biochemistry2025 Sep 1Read Article
Applications: LFA Reactive species: IAV
"Abstract: Objectives
This study investigates diagnosis of upper respiratory diseases with similar clinical symptoms, specifically COVID-19, originated from the SARS-CoV-2 virus, and Influenza infections associated with Influenza viruses. Effective treatment relies on rapid and accurate diagnosis, especially due to pandemic potential. This research aims to develop a multiplex lateral flow assay (LFA) based diagnosis method for detecting SARS-CoV-2 and Influenza A H1N1 viruses simultaneously.
Methods
Lateral flow assay utilizing gold nanoparticles were developed with specific monoclonal antibodies targeting the nucleocapsid (NP) protein of SARS-CoV-2 and the hemagglutinin (HA) protein of Influenza A H1N1. Multiplexing was achieved by immobilizing two different capture antibodies for both targets on the same test. Recombinant antigens were employed to perform analytical assessments of specificity and cross-reactivity.
Results
The limit of detection (LOD) of the developed system in both single and multiplex formats was found to be: 1 ng/mL for SARS-CoV-2 NP, 1 × 103 PFU/mL for active viruses and 5 ng/mL for Influenza A H1N1 HA. Negative control experiments confirmed no cross-reactivity among target antigens, demonstrating high assay specificity. The low LOD values and absence of cross-reactivity indicate excellent analytical sensitivity and specificity. Simultaneous detection of both pathogens offers significant advantages for rapid clinical decision-making and infection control.
Conclusions
Our research presents a potential diagnostic approach utilizing a singular LFA platform for the early and accurate detection of COVID-19 and Influenza infections. The proposed multiplex strategy could improve public health outcomes by facilitating rapid therapeutic intervention and successful disease management during respiratory infection epidemics." Article snippet: Influenza A H1N1 HA Antigen: IAV H1N1Hemagglutinin protein (DAG1604 IAV H1N1), Influenza A H1N1 HA Antibody1: Magic™ Anti-IAV type A Hemagglutinin H1 Monoclonal antibody, Clone C328 N (Cat. DCAB-TJ049 and Influenza A H1N1 HA Antibody-2: Magic™ Anti-IAV type A Hemagglutinin H1 Monoclonal antibody, Clone C329 N (Cat. DCAB-TJ050) were purchased from Creative Diagnostics.
Figure 1. Detection of viral antigens at varying concentrations using the developed lateral flow assay.
My Review for Magic™ Anti-IAV type A Hemagglutinin H1 Monoclonal antibody, Clone C329N
Creative Diagnostics products are for RESEARCH USE ONLY, please make sure your review is research based.
Required fields are marked with *
Terms and conditions:
We will select high-quality review customers and offer a $30 coupon for your next purchase.
All product reviews must be submitted in the English language.
Creative Diagnostics will not share any personal information of applicants, and all information will be treated with strict confidentiality and will not be sold or disclosed to a third party.
COA
Publication 
Loading ......
